NCT06984822View on ClinicalTrials.gov

Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant

NANot yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Diabetic Macular EdemaVisual ImpairmentDiabetes MellitusHyperglycaemia (Diabetic)Oxidative StressVascular Endothelial Growth FactorVEGF
Interventions
DRUG

Anti-VEGF treatment

Intravitreal anti-VEGF treatment

DEVICE

Dexamethasone implant

Intravitreal Dexamethasone implant

OTHER

Anti-VEGF treatment or Dexamethasone implant

Intravitreal anti-VEGF treatment or Intravitreal Dexamethasone implant

Trial Locations (1)

43130

Ögonmottagning Mölndal/SU, Mölndal

All Listed Sponsors
lead

Vastra Gotaland Region

OTHER_GOV

NCT06984822 - Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant | Biotech Hunter | Biotech Hunter